Diary - News
All news ImmunID Announces Agreement with the Singapore Immunology Network (SIgN)
ImmunID, a French Immune Molecular Diagnostics company, today embarked on an agreement with the Singapore Immunology Network (SIgN), a research institute under the Agency of Science, Technology and Research (A*STAR), Singapore. Under the agreement, ImmunID will use its proprietary ImmunTraCkeR® and ImmunIG® tests to evaluate T and B immune repertoire diversity in the blood of patients enrolled in a SIgN-led clinical trial.
